Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography

Molecular Imaging and Biology

Volumn 9, Issue 1, 2007, Pages 43-49

  Wong, Ching Yee Oliver ^a   Thie, Joseph ^b   Parling Lynch, Kelly J ^a   Zakalik, Dana ^a   Wong, Regina H ^c   Gaskill, Marianne ^a   Margolis, Jeffrey H ^a   Hill, Jack ^a   Sukari, Ammar ^a   Chundru, Surya ^a   Fink Bennett, Darlene ^a   Nagle, Conrad ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^c Cranbrook Schools   (United States)

Author keywords

Glucose sensitivity; Lymphoma; PET; Quantum metabolic value

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; ARTICLE; B CELL LYMPHOMA; CALCULATION; CANCER CLASSIFICATION; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; METABOLISM; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STANDARDIZATION; TUMOR BIOPSY;

COHORT STUDIES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 33845982599     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-006-0074-z     Document Type: Article

References (20)

1. Elstrom R, Guan L, Baker G, et al. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876
2. Schoder H, Noy A, Gonen M, et al. (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23:4643-4651
3. Wong CY, Thie J, Parling-Lynch KJ, et al. (2005) Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas. J Nucl Med 46:1659-1663
4. Spaepen K, Stroobants S, Dupont P, et al. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419
5. Jerusalem G, Beguin Y, Fassotte MF, et al. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433
6. Weihrauch MR, Re D, Scheidhauer K, et al. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930-2934
7. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: Comparison with CT. Leuk Lymphoma 39:543-553
8. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027
9. Spaepen K, Stroobants S, Dupont P, et al. (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1356-1363
10. Fisher RI, Gaynor ER, Dahlberg S, et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
11. Spaepen K, Stroobants S, Dupont P, et al. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102:53-59
12. Becherer A, Mitterbauer M, Jaeger U, et al. (2002) Positron emission tomography with [18F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 16:260-267
13. Huang SC (2000) Anatomy of SUV. Standardized uptake value. Nucl Med Biol 27:643-646
14. Thie JA, Smith GT, Hubner KF (2005) 2-Deoxy-2-[F-18]fluoro-D-Glucose-positron emission tomography sensitivity to serum glucose: A survey and diagnostic applications. Mol Imaging Biol 7:1-8
15. Shah N, Hoskin P (2000) The impact of FDG PET imaging on the management of lymphomas. Br J Radiol 73:482-487
16. Schoder H, Meta J, et al. (2001) Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 42:1139-1143
17. Nakamoto Y, Zasadny KR, Minn H, Wahl RL (2002) Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol 4:171-178
18. Thie JA (2004) Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45:1431-1434
19. Barrington SF, O'Doherty MJ (2003) Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 30(Suppl 1):S117-S127
20. Wong CO, Thie J, Gaskill M, et al. (2006) Addressing glucose sensitivity measured by FDG-PET in lung cancers for radiation treatment planning and monitoring. Int J Radiat Oncol Biol Phys 65:132-137